VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · IEX Real-Time Price · USD
0.710
+0.055 (8.40%)
At close: Jul 19, 2024, 4:00 PM
0.760
+0.050 (7.04%)
After-hours: Jul 20, 2024, 12:58 PM EDT
VolitionRx Revenue
VolitionRx had revenue of $797.03K in the twelve months ending March 31, 2024, with 133.06% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $171.54K with 14.50% year-over-year growth. In the year 2023, VolitionRx had annual revenue of $775.30K with 153.04% growth.
Revenue (ttm)
$797.03K
Revenue Growth
+133.06%
P/S Ratio
73.87
Revenue / Employee
$7,246
Employees
110
Market Cap
58.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | 17.10K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 54.97K | - | - |
Dec 31, 2011 | 0 | - | - |
Aug 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rockwell Medical | 86.62M |
HOOKIPA Pharma | 53.55M |
Cryo-Cell International | 31.64M |
ProPhase Labs | 28.72M |
InspireMD | 6.48M |
Adlai Nortye | 5.00M |
Enzo Biochem | 4.72M |
VNRX News
- 12 days ago - Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing - PRNewsWire
- 25 days ago - VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting - PRNewsWire
- 5 weeks ago - Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 7 weeks ago - VolitionRx Limited to Present at Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update - PRNewsWire
- 3 months ago - Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech - PRNewsWire
- 4 months ago - VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update - PRNewsWire